The causal involvement of IL-6 levels in disease remains to be elucidated, but a recent study using a Mendelian randomisation (MR) approach did demonstrate that by using this SNP as instrumental variable, modelling the effects of tocilizumab, that IL-6R signalling has a causal effect on CAD (52). This evidence concerns the gene IL6 and coronary artery disorder.